Market research
CMPS Compass Pathways Plc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.75
- Dividend yield
- Not available
- Beta
- 2.53
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- ISIN
- US20451W1018
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 23.75
- Dividend yield
- Not available
- Beta
- 2.53
About
About Compass Pathways Plc
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CMPS discussion.
5 years, 4 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Other sector with a price to sales ratio of 0.0.
Based on the above factors, COMPASS Pathways plc gets an overall score of 1/5.